Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 29,620,000 shares, a growth of 34.9% from the December 15th total of 21,960,000 shares. Currently, 28.4% of the company’s stock are sold short. Based on an average daily trading volume, of 4,700,000 shares, the short-interest ratio is presently 6.3 days.

Humacyte Price Performance

NASDAQ HUMA traded down $0.05 during trading hours on Thursday, reaching $4.53. 974,979 shares of the stock traded hands, compared to its average volume of 3,264,366. The stock has a 50 day simple moving average of $4.62 and a two-hundred day simple moving average of $5.67. Humacyte has a 1 year low of $2.48 and a 1 year high of $9.97. The company has a market cap of $570.15 million, a price-to-earnings ratio of -3.38 and a beta of 1.32.

Insider Activity at Humacyte

In related news, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now directly owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. The trade was a 25.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock valued at $6,606,799 in the last three months. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC grew its stake in shares of Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after buying an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after buying an additional 8,557 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after buying an additional 8,965 shares during the last quarter. Brookstone Capital Management bought a new position in shares of Humacyte during the fourth quarter valued at about $56,000. Finally, XTX Topco Ltd grew its stake in shares of Humacyte by 48.8% during the third quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock valued at $185,000 after buying an additional 11,172 shares during the last quarter. 44.71% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on HUMA. HC Wainwright restated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Monday. Benchmark upped their price objective on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Finally, BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.